CA1303986C - Action anti-proliferative des arn double brin sur les tumeurs - Google Patents

Action anti-proliferative des arn double brin sur les tumeurs

Info

Publication number
CA1303986C
CA1303986C CA 486814 CA486814A CA1303986C CA 1303986 C CA1303986 C CA 1303986C CA 486814 CA486814 CA 486814 CA 486814 A CA486814 A CA 486814A CA 1303986 C CA1303986 C CA 1303986C
Authority
CA
Canada
Prior art keywords
ifn
cells
interferon
dsrna
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA 486814
Other languages
English (en)
Inventor
William Alvin Carter
Paul O.P. Ts'o
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HEM Pharmaceuticals Corp
Johns Hopkins University
Original Assignee
HEM Pharmaceuticals Corp
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HEM Pharmaceuticals Corp, Johns Hopkins University filed Critical HEM Pharmaceuticals Corp
Priority to CA 486814 priority Critical patent/CA1303986C/fr
Application granted granted Critical
Publication of CA1303986C publication Critical patent/CA1303986C/fr
Expired legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 486814 1985-07-15 1985-07-15 Action anti-proliferative des arn double brin sur les tumeurs Expired CA1303986C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 486814 CA1303986C (fr) 1985-07-15 1985-07-15 Action anti-proliferative des arn double brin sur les tumeurs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 486814 CA1303986C (fr) 1985-07-15 1985-07-15 Action anti-proliferative des arn double brin sur les tumeurs

Publications (1)

Publication Number Publication Date
CA1303986C true CA1303986C (fr) 1992-06-23

Family

ID=4130981

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 486814 Expired CA1303986C (fr) 1985-07-15 1985-07-15 Action anti-proliferative des arn double brin sur les tumeurs

Country Status (1)

Country Link
CA (1) CA1303986C (fr)

Similar Documents

Publication Publication Date Title
EP0113162B1 (fr) Effet antinéoplastiques des acides ds-ribonucléiques sur les cellules des tumeurs
Maluish et al. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon.
Balkwill et al. Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system
Alitalo et al. Acute myelogenous leukaemia with c-myc amplification and double minute chromosomes
CA1320446C (fr) Modulation d'etats cellulaires resistant a la lymphokine a l'aide de dsarn
Ludwig et al. Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial
US6911435B1 (en) Method of treating leukopenia with adenosine
Gao et al. Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2′-β-fluoro-2′, 3′-dideoxyadenosine in peripheral blood mononuclear cells
Cooper et al. Interferons in the treatment of multiple myeloma
CA1303986C (fr) Action anti-proliferative des arn double brin sur les tumeurs
Spiegel Alpha interferons: a clinical overview
Burke et al. A clinical evaluation of a prolonged schedule of cytosine arabinoside (NSC 63878)
LOTZOVÁ et al. Stimulation of NK cell cytotoxic potential of normal donors by two species of recombinant alpha interferon
Kobayashi et al. A phase I study of intermittent infusion cladribine in patients with solid tumors
US8217014B2 (en) Pharmaceutical composition for treatment of blood clotting disorder
AU2002336864A1 (en) Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs
EP1441733A1 (fr) Compositions pharmaceutiques destinees au traitement de la leucemie comprenant des analogues de nucleosides dioxolane
Priestman Interferons and cancer therapy
Lea et al. Action of Miracil D and related compounds on DNA and RNA synthesis in regenerating liver and hepatomas
Young et al. Cancer chemotherapy
US5175005A (en) Method of controlling lung tumor cell metastasis
Reiter et al. Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: cytotoxic effect and MHC-unrestricted killer cell regulation
Bruntsch et al. Lack of response in nine patients with breast cancer treated with fibroblast interferon
Stolfi et al. Enhancement of anticancer agent activity by selective inhibitiion of rapidly proliferating tissues of the host
Papac Clinical and hematologic studies with 1-β-D-arabinosylcytosine

Legal Events

Date Code Title Description
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121205